Home
Home

M&A

Endo Health new CEO suggests near-term sale unlikely, says Wells Fargo

Endo Health new CEO suggests near-term sale unlikely, says Wells Fargo
The Fly on the Wall

China Biotech Week In Review: Regeneron Pharma, Bayer Start New Trial For DME Treatment

China Biotech Week In Review: Regeneron Pharma, Bayer Start New Trial For DME Treatment
Seeking Alpha

BGI-Shenzhen Extends Tender Offer For Complete Genomics, inc.

BGI-Shenzhen Extends Tender Offer For Complete Genomics, inc.
Yahoo/PR Newswire

Bausch & Lomb Owner Said to Seek Banks for IPO as Sale Falters

Bausch & Lomb Owner Said to Seek Banks for IPO as Sale Falters
Bloomberg

InterMune Sale Looms as Lung Drug Nears FDA Nod: Real M&A

InterMune Sale Looms as Lung Drug Nears FDA Nod: Real M&A
Bloomberg

Biomarin: This Mid-Cap Pharmaceutical is a Prime Takeover Target

Biomarin: This Mid-Cap Pharmaceutical is a Prime Takeover Target
Motley Fool

China Biotech In Review: Amgen To Build China Presence With Partnerships / M&A

China Biotech In Review: Amgen To Build China Presence With Partnerships / M&A
Seeking Alpha

Mylan in exclusive talks to buy Strides Arcolab’s injectables unit

Mylan in exclusive talks to buy Strides Arcolab’s injectables unit
Economic Times, India

Cardinal Health Agrees to Buy AssuraMed for $2.07 Billion

Cardinal Health Agrees to Buy AssuraMed for $2.07 Billion
Bloomberg

Allergan and MAP: Pharma Buyout With a 60% Premium

Allergan and MAP: Pharma Buyout With a 60% Premium
Motley Fool